NDLI: Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.

Please wait, while we are loading the content...

Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial.

Pharmacokinetics of betamethasone after single-dose intramuscular administration of betamethasone phosphate and betamethasone acetate to healthy subjects.

Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide.

Ulipristal acetate: review of the efficacy and safety of a newly approved agent for emergency contraception.

Prescription drug use in pregnancy: a retrospective, population-based study in British Columbia, Canada (2001-2006).

Assessment of the efficacy and safety profiles of aspirin and acetaminophen with codeine: results from 2 randomized, controlled trials in individuals with tension-type headache and postoperative dental pain.

Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study.

Estradiol valerate/dienogest: a novel combined oral contraceptive.

Head lice and the use of spinosad.

Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression: a retrospective US claims study.

Changes in MIC within a global collection of Acinetobacter baumannii collected as part of the Tigecycline Evaluation and Surveillance Trial, 2004 to 2009.

Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.

Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.

The effect of a 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART: a randomized, placebo-controlled pilot trial.

Symptomatic management of fever by Swiss board-certified pediatricians: results from a cross-sectional, Web-based survey.

Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.

Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.

Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database.

Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosis.

Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model.

Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis.

Year: 2011 Volume: 33

Year: 2010 Volume: 32

Year: 2009 Volume: 31

Year: 2008 Volume: 30

Year: 2008 Volume: 30 Spec No

Year: 2008 Volume: 30 Pt 2

Year: 2007 Volume: 29

Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Lancaster, Jason W. Matthews, S. James
Description	Country affiliation: United States Author Affiliation: Lancaster JW ( Department of Pharmacy Practice, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts, USA.)
Abstract	BACKGROUND: Fidaxomicin, a macrolide antibiotic, was the first medication for the management of Clostridium difficile infections (CDI) to be approved by the US Food and Drug Administration in more than 20 years. OBJECTIVE: This article reviews published literature on fidaxomicin for management of CDI, including its chemistry, spectrum of activity, pharmacokinetic properties, pharmacodynamics, therapeutic efficacy, adverse events, dosing, administration, and pharmacoeconomic considerations. METHODS: Pertinent English-language literature was reviewed through searches of MEDLINE, EMBASE, and BIOSIS from 1975 through September 2011. Reference lists of identified publications and published abstracts from the Interscience Conference on Antimicrobial Agents and Chemotherapy meetings were also reviewed. Search terms included, but were not limited to, fidaxomicin, difimicin, lipiarmycin, tiacumicin B, OPT-80, Clostridium spp, and diarrhea. RESULTS: A total of 79 publications were identified and 10 were excluded; 6 review articles and 4 abstracts that were later published as articles. Fidaxomicin's in vitro profile is favorable compared with oral metronidazole and vancomycin, with minimum inhibitory concentrations against C difficile that are 2 dilutions lower. From the 2 published Phase III trials, fidaxomicin was deemed to be noninferior in the treatment of mild to moderate CDI compared with oral vancomycin. Recurrence rates for all strains of CDI were lower with fidaxomicin than vancomycin. Adverse events associated with fidaxomicin were similar to placebo, with nausea and vomiting being the most common. Although no pharmacoeconomic studies have compared fidaxomicin with metronidazole or vancomycin, the current price exceeds \$2500 (US) per treatment course. CONCLUSIONS: Reports suggest that fidaxomicin is noninferior to oral vancomycin in the treatment of mild or moderate CDI, although no published comparisons with metronidazole exist to date. Additionally, fidaxomicin improved outcomes compared with oral vancomycin in terms of rates of relapse and recurrent CDI, and in patients who might require concomitant antibiotics. Prospective, randomized studies comparing fidaxomicin with metronidazole in the treatment of mild or moderate CDI, as well as against vancomycin for severe CDI, should be undertaken to clarify the exact role of fidaxomicin in clinical practice.
File Format	HTM / HTML
ISSN	01492918
Issue Number	1
Volume Number	34
e-ISSN	1879114X
Journal	Clinical Therapeutics
Language	English
Publisher	Elsevier
Publisher Date	2012-01-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Aminoglycosides Therapeutic Use Anti-bacterial Agents Clostridium Difficile Pathogenicity Enterocolitis, Pseudomembranous Drug Therapy Administration & Dosage Adverse Effects Economics Pharmacokinetics Animals Drug Costs Drug Resistance, Bacterial Microbiology Humans Recurrence Treatment Outcome Journal Article Review
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Fidaxomicin for the treatment of Clostridium difficile infections.

Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection.

Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.

A Clostridium difficile-fertozések epidemiológiája, betegségterhe és terápiája.

Role of fidaxomicin for the treatment of Clostridium difficile infection.

A Clostridium difficile-fertozések antibiotikum-terápiája. A tudományos bizonyítékok szisztematikus áttekintése és metaanalízise.

Collateral damage. The rise of resistant C. difficile.

Future novel therapeutic agents for Clostridium difficile infection.

Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.

Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.

Similar Documents

Fidaxomicin for the treatment of Clostridium difficile infections.

Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection.

Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.

A Clostridium difficile-fertozések epidemiológiája, betegségterhe és terápiája.

Role of fidaxomicin for the treatment of Clostridium difficile infection.

A Clostridium difficile-fertozések antibiotikum-terápiája. A tudományos bizonyítékok szisztematikus áttekintése és metaanalízise.

Collateral damage. The rise of resistant C. difficile.

Future novel therapeutic agents for Clostridium difficile infection.

Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.

Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.